Browsing ICR Divisions by author "Tutt, Andrew"
Now showing items 21-40 of 63
-
Genomic Evolution of Breast Cancer Metastasis and Relapse.
Yates, LR; Knappskog, S; Wedge, D; Farmery, JHR; Gonzalez, S; et al. (CELL PRESS, 2017-08-14)Patterns of genomic evolution between primary and metastatic breast cancer have not been studied in large numbers, despite patients with metastatic breast cancer having dismal survival. We sequenced whole genomes or a panel ... -
Genomic profiling and pre-clinical modelling of breast cancer leptomeningeal metastasis reveals acquisition of a lobular-like phenotype.
Fitzpatrick, A; Iravani, M; Mills, A; Vicente, D; Alaguthurai, T; et al. (Springer Science and Business Media LLC, 2023-11-16)Breast cancer leptomeningeal metastasis (BCLM), where tumour cells grow along the lining of the brain and spinal cord, is a devastating development for patients. Investigating this metastatic site is hampered by difficulty ... -
Histological scoring of immune and stromal features in breast and axillary lymph nodes is prognostic for distant metastasis in lymph node-positive breast cancers.
Grigoriadis, A; Gazinska, P; Pai, T; Irhsad, S; Wu, Y; et al. (WILEY, 2018-01-08)The prognostic importance of lymph node (LN) status and tumour-infiltrating lymphocytes (TILs), is well established, particularly TILs in triple negative breast cancers (TNBCs). So far, few studies have interrogated changes ... -
Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer.
Chopra, N; Tovey, H; Pearson, A; Cutts, R; Toms, C; et al. (NATURE PORTFOLIO, 2020-05-29)Triple negative breast cancer (TNBC) encompasses molecularly different subgroups, with a subgroup harboring evidence of defective homologous recombination (HR) DNA repair. Here, within a phase 2 window clinical trial, RIO ... -
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.
Davies, H; Glodzik, D; Morganella, S; Yates, LR; Staaf, J; et al. (NATURE PUBLISHING GROUP, 2017-04-01)Approximately 1-5% of breast cancers are attributed to inherited mutations in BRCA1 or BRCA2 and are selectively sensitive to poly(ADP-ribose) polymerase (PARP) inhibitors. In other cancer types, germline and/or somatic ... -
A HUWE1 defect causes PARP inhibitor resistance by modulating the BRCA1-∆11q splice variant.
Pettitt, SJ; Shao, N; Zatreanu, D; Frankum, J; Bajrami, I; et al. (SPRINGERNATURE, 2023-09-01)Although PARP inhibitors (PARPi) now form part of the standard-of-care for the treatment of homologous recombination defective cancers, de novo and acquired resistance limits their overall effectiveness. Previously, ... -
Inhibited, trapped or adducted: the optimal selective synthetic lethal mix for BRCAness.
Tutt, A (OXFORD UNIV PRESS, 2018-01-01) -
Integrated genomics and functional validation identifies malignant cell specific dependencies in triple negative breast cancer.
Patel, N; Weekes, D; Drosopoulos, K; Gazinska, P; Noel, E; et al. (NATURE PUBLISHING GROUP, 2018-03-13)Triple negative breast cancers (TNBCs) lack recurrent targetable driver mutations but demonstrate frequent copy number aberrations (CNAs). Here, we describe an integrative genomic and RNAi-based approach that identifies ... -
Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727).
Tovey, H; Sipos, O; Parker, JS; Hoadley, KA; Quist, J; et al. (AMER ASSOC CANCER RESEARCH, 2023-09-15)PURPOSE: The TNT trial (NCT00532727) showed no evidence of carboplatin superiority over docetaxel in metastatic triple-negative breast cancer (mTNBC), but carboplatin benefit was observed in the germline BRCA1/2 mutation ... -
Integrin-Mediated Macrophage Adhesion Promotes Lymphovascular Dissemination in Breast Cancer.
Evans, R; Flores-Borja, F; Nassiri, S; Miranda, E; Lawler, K; et al. (CELL PRESS, 2019-05-14)Lymphatic vasculature is crucial for metastasis in triple-negative breast cancer (TNBC); however, cellular and molecular drivers controlling lymphovascular metastasis are poorly understood. We define a macrophage-dependent ... -
Landscape of somatic mutations in 560 breast cancer whole-genome sequences.
Nik-Zainal, S; Davies, H; Staaf, J; Ramakrishna, M; Glodzik, D; et al. (NATURE PUBLISHING GROUP, 2016-06-02)We analysed whole-genome sequences of 560 breast cancers to advance understanding of the driver mutations conferring clonal advantage and the mutational processes generating somatic mutations. We found that 93 protein-coding ... -
Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer.
Harvey-Jones, E; Raghunandan, M; Robbez-Masson, L; Magraner-Pardo, L; Alaguthurai, T; et al. (ELSEVIER, 2024-01-19)BACKGROUND: Resistance to therapies that target homologous recombination deficiency (HRD) in breast cancer limits their overall effectiveness. Multiple, preclinically validated, mechanisms of resistance have been proposed, ... -
Loss of E-cadherin leads to Id2-dependent inhibition of cell cycle progression in metastatic lobular breast cancer.
Rätze, MAK; Koorman, T; Sijnesael, T; Bassey-Archibong, B; van de Ven, R; et al. (SPRINGERNATURE, 2022-05-20)Invasive lobular breast carcinoma (ILC) is characterized by proliferative indolence and long-term latency relapses. This study aimed to identify how disseminating ILC cells control the balance between quiescence and cell ... -
MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cells.
Zelceski, A; Francica, P; Lingg, L; Mutlu, M; Stok, C; et al. (CELL PRESS, 2023-05-30)The PSMC3IP-MND1 heterodimer promotes meiotic D loop formation before DNA strand exchange. In genome-scale CRISPR-Cas9 mutagenesis and interference screens in mitotic cells, depletion of PSMC3IP or MND1 causes sensitivity ... -
Molecular alterations in triple-negative breast cancer-the road to new treatment strategies.
Denkert, C; Liedtke, C; Tutt, A; von Minckwitz, G (ELSEVIER SCIENCE INC, 2017-06-17)Triple-negative breast cancer is a heterogeneous disease and specific therapies have not been available for a long time. Therefore, conventional chemotherapy is still considered the clinical state of the art. Different ... -
Mouse mammary stem cells express prognostic markers for triple-negative breast cancer.
Soady, KJ; Kendrick, H; Gao, Q; Tutt, A; Zvelebil, M; et al. (BMC, 2015-03-04)INTRODUCTION: Triple-negative breast cancer (TNBC) is a heterogeneous group of tumours in which chemotherapy, the current mainstay of systemic treatment, is often initially beneficial but with a high risk of relapse and ... -
New Roles of Poly(ADP-Ribose) Polymerase Inhibitors in the Treatment of Breast Cancer.
Harvey-Jones, E; Vinas Villaro, G; Tutt, A (ASSOC DEVELOPPEMENT COMMUNICATION CANCEROLOGIQUE, 2021-11-01)Since the proof of concept of synthetic lethality between poly(ADP-ribose) polymerase inhibition and loss of BRCA1/2 homologous recombination (HR) function in preclinical models and early phase clinical trials, poly(ADP-ribose) ... -
Next-Generation Sequencing and Image-Guided Tissue Sampling: A Primer for Interventional Radiologists.
Yeung, J; Fotiadis, N; Diamantopoulos, A; Tutt, A; Roxanis, I; et al. (Elsevier BV, 2023-03-01)The discovery of increasing numbers of actionable molecular and gene targets for cancer treatment has driven the demand for tissue sampling for next-generation sequencing (NGS). Requirements for sequencing can be very ... -
Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO Study.
Turner, NC; Balmaña, J; Poncet, C; Goulioti, T; Tryfonidis, K; et al. (AMER ASSOC CANCER RESEARCH, 2021-10-15)PURPOSE: To investigate the activity of niraparib in patients with germline-mutated BRCA1/2 (gBRCAm) advanced breast cancer. PATIENTS AND METHODS: BRAVO was a randomized, open-label phase III trial. Eligible patients had ... -
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.
Geyer, CE; Garber, JE; Gelber, RD; Yothers, G; Taboada, M; et al. (ELSEVIER, 2022-10-10)BACKGROUND: The randomized, double-blind OlympiA trial compared 1 year of the oral poly(adenosine diphosphate-ribose) polymerase inhibitor, olaparib, to matching placebo as adjuvant therapy for patients with pathogenic or ...